Table 1.
Baseline Demographic, Clinical, and Laboratory Characteristics of the 220,727 Patients With Chronic Liver Diseases With and Without Cirrhosis Included in the Analysis
| Characteristic | Noncirrhosis/negative (n = 128,864) | Noncirrhosis/positive (n = 29,446) | Cirrhosis/negative (n = 53,476) | Cirrhosis/positive (n = 8941) | |||
|---|---|---|---|---|---|---|---|
| Sex, female | 68,209 (53) | 15,947 (54) | 23,479 (44) | 4009 (45) | |||
| Age | 54 (42–64) | 53 (41–62) | 60 (50–67) | 61 (51–68) | |||
| 18–29 y | 8732 (7) | 2163 (7) | 1431 (3) | 229 (3) | |||
| 30–49 y | 42,408 (33) | 10,365 (35) | 11,315 (21) | 1696 (19) | |||
| 50–64 y | 48,582 (38) | 10,952 (37) | 22,528 (42) | 3702 (41) | |||
| 65+ y | 29,142 (23) | 5966 (20) | 18,202 (34) | 3314 (37) | |||
| Race/ethnicity | |||||||
| White | 80,114 (62) | 15,995 (54) | 35,308 (66) | 5055 (57) | |||
| Black/African-American | 19,524 (15) | 4291 (15) | 8701 (16) | 1701 (19) | |||
| Hispanic | 16,898 (13) | 5524 (19) | 5424 (10) | 1289 (14) | |||
| Asian | 4639 (4) | 968 (3) | 1203 (2) | 195 (2) | |||
| Unknown/other | 7689 (6) | 2668 (9) | 2840 (5) | 701 (8) | |||
| Height, cma | 170 (163–178) | 170 (163–178) | 170 (163–178) | 170 (163–178) | |||
| Weight, kga | 90 (75–107) | 94 (79–112) | 83 (69–100) | 86 (72–104) | |||
| BMI, kg/m2,a | 31 (27–37) | 33 (28–38) | 29 (24–34) | 30 (25–36) | |||
| BMI ≥30 kg/m2 | 46,239 (36) | 9405 (32) | 15,198 (28) | 2401 (27) | |||
| Liver disease etiology | |||||||
| NAFLD | 85,420 (66) | 21,237 (72) | 17,753 (33) | 3492 (39) | |||
| Hepatitis C | 27,657 (21) | 4691 (16) | 10,577 (20) | 1707 (19) | |||
| AALD | 8017 (6) | 1941 (7) | 17,980 (34) | 2518 (28) | |||
| Hepatitis B | 5406 (4) | 1170 (4) | 2173 (4) | 399 (4) | |||
| Cholestatic | 785 (1) | 100 (0) | 3158 (6) | 522 (6) | |||
| Autoimmune | 1579 (1) | 307 (1) | 1835 (3) | 303 (3) | |||
| Decompensated cirrhosis | 36,930 (69) | 5993 (67) | |||||
| Modified CCIb | 1 (0–3) | 1 (0–3) | 2 (0–5) | 3 (1–6) | |||
| Comorbidities | |||||||
| Diabetes | 39,865 (31) | 10,510 (36) | 20,954 (39) | 4339 (49) | |||
| Chronic renal disease | 11,660 (9) | 2651 (9) | 10,235 (19) | 2228 (25) | |||
| Congestive heart failure | 10,615 (8) | 2169 (7) | 10,235 (19) | 2044 (23) | |||
| Chronic pulmonary disease | 36,229 (28) | 7,391 (25) | 16,271 (30) | 2859 (32) | |||
| Region | |||||||
| Northeast | 14,940 (12) | 2664 (9) | 4273 (8) | 791 (9) | |||
| Midwest | 20,098 (16) | 4498 (15) | 10,345 (19) | 1574 (18) | |||
| South | 22,066 (17) | 3670 (12) | 9596 (18) | 1142 (13) | |||
| West | 16,462 (13) | 2560 (9) | 6367 (12) | 657 (7) | |||
| Other | 55,298 (43) | 16,054 (55) | 22,895 (43) | 4777 (53) | |||
| Laboratory testsa | |||||||
| Albumin, g/L | 4.0 (3.6–4.4) | 3.7 (3.1–4.1) | 3.4 (2.8–4.0) | 3.1 (2.6–3.7) | |||
| AST, u/L | 28 (20–47) | 33 (22–52) | 41 (25–74) | 43 (27–77) | |||
| ALT, u/L | 31 (19–56) | 37 (22–66) | 29 (18–51) | 32 (20–57) | |||
| Total bilirubin, mg/dL | 0.5 (0.4–0.7) | 0.4 (0.3–0.7) | 0.9 (0.5–2.0) | 0.8 (0.4–1.8) | |||
| Creatinine, mg/dL | 0.8 (0.7–1.0) | 0.8 (0.6–1.0) | 0.9 (0.7–1.2) | 0.9 (0.7–1.4) | |||
| INR | 241 (190–301) | 239 (184–311) | 174 (106–254) | 163 (99–252) | |||
| Platelet, 109/L | 13.0 (11.4–14.3) | 12.9 (11.4–14.1) | 11.3 (9.3–13.1) | 10.9 (9.0–12.8) | |||
| Hemoglobin, g/dL | 1.1 (1.0–1.2) | 1.1 (1.0–1.2) | 1.3 (1.1–1.7) | 1.3 (1.1–1.8) | |||
| Neutrophil, 109/L | 4.8 (3.4–6.8) | 4.2 (3.0–6.2) | 4.3 (2.9–6.6) | 4.3 (2.9–6.6) | |||
| Lymphocyte, 109/L | 1.8 (1.3–2.5) | 1.4 (1.0–2.0) | 1.3 (0.8–2.0) | 1.1 (0.7–1.7) | |||
| Neutrophil/lymphocyte ratio | 2.8 (1.8–4.6) | 2.5 (1.7–4.2) | 3.2 (2.0–5.6) | 3.7 (2.1–7.1) | |||
| MELD–Nac | 9 (7–13) | 10 (8–13) | 16 (11–24) | 17 (11–24) | |||
NOTE. Continuous variables are presented as median (IQR), ordinal and categorical variables are presented as n (%).
ALT, alanine transaminase; AST, aspartate transaminase; INR, international normalized ratio.
a
Height, weight, BMI, and laboratory tests exhibit a range of missingness from 38% to 88% of the total sample.
b
Modified CCI was calculated based on the original CCI score, excluding weights for “mild liver disease” and “severe liver disease.”
c
MELD-Na scores were calculated for 17,653 patients, which represent 8% of the total sample.